Repligen (RGN) Stock Forecast & Price Target

Compare

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RGN Analyst Ratings

Strong Buy

13 Buy

2 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Repligen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RGN Stock 12 Month Forecast

Average Price Target

€150.65

▲(22.83% Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Repligen in the last 3 months. The average price target is €150.65 with a high forecast of €187.57 and a low forecast of €115.10. The average price target represents a 22.83% change from the last price of €122.65.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"99":"€99","188":"€188","121.25":"€121.3","143.5":"€143.5","165.75":"€165.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":187.57244,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€187.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":150.64624738,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€150.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":115.10127,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€115.10</span>\n  </div></div>","useHTML":true}}],"tickPositions":[99,121.25,143.5,165.75,188],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.65,117.4901876923077,123.3303753846154,129.1705630769231,135.01075076923078,140.85093846153848,146.69112615384614,152.53131384615386,158.37150153846153,164.21168923076925,170.05187692307692,175.89206461538464,181.7322523076923,{"y":187.57244,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.65,114.64971133692308,117.64942267384616,120.64913401076923,123.64884534769232,126.64855668461539,129.64826802153846,132.64797935846155,135.64769069538463,138.6474020323077,141.64711336923077,144.64682470615384,147.64653604307694,{"y":150.64624738,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,111.65,111.91548230769232,112.18096461538462,112.44644692307693,112.71192923076923,112.97741153846154,113.24289384615385,113.50837615384616,113.77385846153847,114.03934076923078,114.30482307692307,114.57030538461538,114.83578769230769,{"y":115.10127,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":135.05,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.05,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":141.3,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.3,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.75,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.45,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.95,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.65,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€187.57

Average Price Target€150.65

Lowest Price Target€115.10

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Luke Sergott

Barclays

€127.79→€136.31

Buy

11.14%

Upside

Reiterated

10/02/25

Repligen price target raised to $160 from $150 at BarclaysRepligen price target raised to $160 from $150 at Barclays

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

10/01/25

Analysts' Top Healthcare Picks: Maze Therapeutics, Inc. (MAZE), Repligen (RGEN)

Sidharth Sahoo

HSBC

€127.79

Buy

4.19%

Upside

Initiated

09/30/25

Repligen's Growth Potential: A Buy Rating Backed by Innovation and Strategic Positioning

Paul Knight

KeyBanc

€187.43

Buy

52.81%

Upside

Reiterated

09/23/25

KeyBanc Sticks to Their Buy Rating for Repligen (RGEN)

Daniel Markowitz CFA

Evercore ISI

€110.75→€132.05

Buy

7.66%

Upside

Upgraded

09/22/25

Repligen upgraded to Outperform from In Line at Evercore ISIRepligen upgraded to Outperform from In Line at Evercore ISI

Jack Scalprey

TR | OpenAI - 4o

€106.49→€104.79

Hold

-14.56%

Downside

Reiterated

09/18/25

AI Generated ArticleAI Generated Article

Brendan Smith

TD Cowen

€170.39

Buy

38.92%

Upside

Reiterated

09/17/25

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Repligen (NASDAQ: RGEN) and Exelixis (NASDAQ: EXEL)

Daniel Arias

Stifel Nicolaus

€176.35

Buy

43.78%

Upside

Reiterated

09/16/25

Stifel Nicolaus Keeps Their Buy Rating on Repligen (RGEN)

Matthew Stanton, CFA

Jefferies

€123.53→€115.01

Hold

-6.23%

Downside

Reiterated

09/11/25

Jefferies Remains a Hold on Repligen (RGEN)Jefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $135.00 (from $145.00) while maintaining a Hold rating.

Puneet Souda

Leerink Partners

€170.39

Buy

38.92%

Upside

Reiterated

09/11/25

Analysts Are Bullish on Top Healthcare Stocks: Repligen (RGEN), Insulet (PODD)

Ram Selvaraju

H.C. Wainwright

€153.35

Buy

25.03%

Upside

Reiterated

09/03/25

Analysts' Top Healthcare Picks: Repligen (RGEN), Alpha Tau Medical Ltd (DRTS)

Conor McNamara

RBC Capital

€173.8→€174.65

Buy

42.40%

Upside

Reiterated

09/02/25

RBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)

Brandon Couillard

Wells Fargo

€153.35→€149.09

Buy

21.56%

Upside

Reiterated

07/30/25

Wells Fargo Sticks to Their Buy Rating for Repligen (RGEN)

Matt Larew

William Blair

―

Buy

―

Reiterated

07/29/25

Repligen's Strong Q2 Performance and Growth Prospects Justify Buy Rating

Kyle Mikson CFA

Canaccord Genuity

€127.79

Hold

4.19%

Upside

Reiterated

07/29/25

Repligen (RGEN) Gets a Hold from Canaccord Genuity

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Luke Sergott

Barclays

€127.79→€136.31

Buy

11.14%

Upside

Reiterated

10/02/25

Repligen price target raised to $160 from $150 at BarclaysRepligen price target raised to $160 from $150 at Barclays

Matt Hewitt

Craig-Hallum

―

Buy

―

Reiterated

10/01/25

Analysts' Top Healthcare Picks: Maze Therapeutics, Inc. (MAZE), Repligen (RGEN)

Sidharth Sahoo

HSBC

€127.79

Buy

4.19%

Upside

Initiated

09/30/25

Repligen's Growth Potential: A Buy Rating Backed by Innovation and Strategic Positioning

Paul Knight

KeyBanc

€187.43

Buy

52.81%

Upside

Reiterated

09/23/25

KeyBanc Sticks to Their Buy Rating for Repligen (RGEN)

Daniel Markowitz CFA

Evercore ISI

€110.75→€132.05

Buy

7.66%

Upside

Upgraded

09/22/25

Repligen upgraded to Outperform from In Line at Evercore ISIRepligen upgraded to Outperform from In Line at Evercore ISI

Jack Scalprey

TR | OpenAI - 4o

€106.49→€104.79

Hold

-14.56%

Downside

Reiterated

09/18/25

AI Generated ArticleAI Generated Article

Brendan Smith

TD Cowen

€170.39

Buy

38.92%

Upside

Reiterated

09/17/25

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Repligen (NASDAQ: RGEN) and Exelixis (NASDAQ: EXEL)

Daniel Arias

Stifel Nicolaus

€176.35

Buy

43.78%

Upside

Reiterated

09/16/25

Stifel Nicolaus Keeps Their Buy Rating on Repligen (RGEN)

Matthew Stanton, CFA

Jefferies

€123.53→€115.01

Hold

-6.23%

Downside

Reiterated

09/11/25

Jefferies Remains a Hold on Repligen (RGEN)Jefferies analyst Matthew Stanton lowered the price target on Repligen (NASDAQ: RGEN) to $135.00 (from $145.00) while maintaining a Hold rating.

Puneet Souda

Leerink Partners

€170.39

Buy

38.92%

Upside

Reiterated

09/11/25

Analysts Are Bullish on Top Healthcare Stocks: Repligen (RGEN), Insulet (PODD)

Ram Selvaraju

H.C. Wainwright

€153.35

Buy

25.03%

Upside

Reiterated

09/03/25

Analysts' Top Healthcare Picks: Repligen (RGEN), Alpha Tau Medical Ltd (DRTS)

Conor McNamara

RBC Capital

€173.8→€174.65

Buy

42.40%

Upside

Reiterated

09/02/25

RBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)

Brandon Couillard

Wells Fargo

€153.35→€149.09

Buy

21.56%

Upside

Reiterated

07/30/25

Wells Fargo Sticks to Their Buy Rating for Repligen (RGEN)

Matt Larew

William Blair

―

Buy

―

Reiterated

07/29/25

Repligen's Strong Q2 Performance and Growth Prospects Justify Buy Rating

Kyle Mikson CFA

Canaccord Genuity

€127.79

Hold

4.19%

Upside

Reiterated

07/29/25

Repligen (RGEN) Gets a Hold from Canaccord Genuity

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Repligen

1 Month

xxx

Success Rate

12/20 ratings generated profit

Average Return

+2.24%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +2.24% per trade.

3 Months

xxx

Success Rate

7/11 ratings generated profit

Average Return

+0.55%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +0.55% per trade.

1 Year

Daniel AriasStifel Nicolaus

Success Rate

12/24 ratings generated profit

Average Return

+15.02%

reiterated a buy rating 18 days ago

Copying Daniel Arias's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +15.02% per trade.

2 Years

xxx

Success Rate

8/24 ratings generated profit

Average Return

+18.23%

reiterated a xxx

rating 18 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 33.33% of your transactions generating a profit, with an average return of +18.23% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RGN Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, RGN has received 13 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. RGN average Analyst price target in the past 3 months is 150.65.

Each month's total comprises the sum of three months' worth of ratings.

RGN Financial Forecast

RGN Earnings Forecast

Next quarter’s earnings estimate for RGN is €0.35 with a range of €0.32 to €0.38. The previous quarter’s EPS was €0.32. RGN beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year RGN has Preformed in-line its overall industry.

RGN Sales Forecast

Next quarter’s sales forecast for RGN is €154.82M with a range of €151.63M to €158.16M. The previous quarter’s sales results were €155.32M. RGN beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year RGN has Preformed in-line its overall industry.

RGN Stock Forecast FAQ

What is DE:RGN’s average 12-month price target, according to analysts?

Based on analyst ratings, Repligen Corp’s 12-month average price target is 150.65.

What is DE:RGN’s upside potential, based on the analysts’ average price target?

Repligen Corp has 22.83% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Repligen Corp a Buy, Sell or Hold?

Repligen Corp has a consensus rating of Strong Buy, which is based on 13 buy ratings, 2 hold ratings and 0 sell ratings.

What is Repligen Corp’s share price target?

The average share price target for Repligen Corp is 150.65. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €187.57 ,and the lowest forecast is €115.10. The average share price target represents 22.83% Increase from the current price of €122.65.

What do analysts say about Repligen Corp?

Repligen Corp’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of Repligen Corp?

To buy shares of DE:RGN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Repligen (RGN) Stock Forecast & Price Target

RGN Analyst Ratings

RGN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Repligen

RGN Analyst Recommendation Trends

RGN Financial Forecast

RGN Earnings Forecast

RGN Sales Forecast

RGN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts